Effect of mutations in TrkA gene found in insensitivity to congenital pain on cell...
| Full text | |
| Author(s): |
Pena, Darlene A.
[1]
;
Duarte, Mariana Lemos
[2]
;
Pramio, Dimitrius T.
[1]
;
Devi, Lakshmi A.
[2]
;
Schechtman, Deborah
[1]
Total Authors: 5
|
| Affiliation: | [1] Univ Sao Paulo, Chem Inst, Dept Biochem, BR-05508220 Sao Paulo - Brazil
[2] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 - USA
Total Affiliations: 2
|
| Document type: | Review article |
| Source: | PROTEOMES; v. 6, n. 4 DEC 2018. |
| Web of Science Citations: | 2 |
| Abstract | |
It is well accepted that treatment of chronic pain with morphine leads to opioid receptor (MOR) desensitization and the development of morphine tolerance. MOR activation by the selective peptide agonist, D-Ala2, N-MePhe4, Gly-ol]-enkephalin(DAMGO), leads to robust G protein receptor kinase activation, -arrestin recruitment, and subsequent receptor endocytosis, which does not occur in an activation by morphine. However, MOR activation by morphine induces receptor desensitization, in a Protein kinase C (PKC) dependent manner. PKC inhibitors have been reported to decrease receptor desensitization, reduce opiate tolerance, and increase analgesia. However, the exact role of PKC in these processes is not clearly delineated. The difficulties in establishing a particular role for PKC have been, in part, due to the lack of reagents that allow the selective identification of PKC targets. Recently, we generated a conformation state-specific anti-PKC antibody that preferentially recognizes the active state of this kinase. Using this antibody to selectively isolate PKC substrates and a proteomics strategy to establish the identity of the proteins, we examined the effect of morphine treatment on the PKC targets. We found an enhanced interaction of a number of proteins with active PKC, in the presence of morphine. In this article, we discuss the role of these proteins in PKC-mediated MOR desensitization and analgesia. In addition, we posit a role for some of these proteins in mediating pain by TrKA activation, via the activation of transient receptor potential cation channel subfamily V member 1 (TRPV1). Finally, we discuss how these new PKC interacting proteins and pathways could be targeted for the treatment of pain. (AU) | |
| FAPESP's process: | 15/21786-8 - Development, characterization and applications of PKC activation specific antibodies |
| Grantee: | Deborah Schechtman |
| Support type: | Regular Research Grants |